122 related articles for article (PubMed ID: 22273319)
1. Recurrence risk after resection of gastrointestinal stromal tumors: size is not all that matters... The consequences of tumor rupture.
Han D; Deneve J; Gonzalez RJ
Am Surg; 2012 Jan; 78(1):74-9. PubMed ID: 22273319
[TBL] [Abstract][Full Text] [Related]
2. Management of localized gastrointestinal stromal tumors and adjuvant therapy with imatinib.
López RL; del Muro XG
Anticancer Drugs; 2012 Jun; 23 Suppl():S3-6. PubMed ID: 22739667
[TBL] [Abstract][Full Text] [Related]
3. Tumor rupture exposes the patient to an increased risk of relapse, regardless of the size and number of mitoses.
Quintero CB; Cubedo R
Anticancer Drugs; 2012 Jun; 23 Suppl():S1-2. PubMed ID: 22739664
[No Abstract] [Full Text] [Related]
4. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes.
Rutkowski P; Bylina E; Wozniak A; Nowecki ZI; Osuch C; Matlok M; Switaj T; Michej W; Wroński M; Głuszek S; Kroc J; Nasierowska-Guttmejer A; Joensuu H
Eur J Surg Oncol; 2011 Oct; 37(10):890-6. PubMed ID: 21737227
[TBL] [Abstract][Full Text] [Related]
5. A multi-centre analysis of the impact of updated risk stratification on follow-up of gastric gastro-intestinal stromal tumours in the post-imatinib era.
Reece-Smith AM; MacGoey P; Shah MA; Leeder P; Andrew DR; McCulloch T; Parsons SL
Eur J Surg Oncol; 2012 Jun; 38(6):484-9. PubMed ID: 22342866
[TBL] [Abstract][Full Text] [Related]
6. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.
Cao H; Zhang Y; Wang M; Shen DP; Sheng ZY; Ni XZ; Wu ZY; Liu Q; Shen YY; Song YY
Chin Med J (Engl); 2010 Jan; 123(2):131-6. PubMed ID: 20137358
[TBL] [Abstract][Full Text] [Related]
7. Gastric GIST: a single institutional retrospective experience with surgical treatment for primary disease.
An JY; Choi MG; Noh JH; Sohn TS; Kang WK; Park CK; Kim S
Eur J Surg Oncol; 2007 Oct; 33(8):1030-5. PubMed ID: 17428635
[TBL] [Abstract][Full Text] [Related]
8. Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors: current overall survival after primary tumor resection.
Rutkowski P; Wozniak A; Dębiec-Rychter M; Kąkol M; Dziewirski W; Zdzienicki M; Ptaszynski K; Jurkowska M; Limon J; Siedlecki JA
Cancer; 2011 Nov; 117(21):4916-24. PubMed ID: 21456019
[TBL] [Abstract][Full Text] [Related]
9. Different factors are responsible for predicting relapses after primary tumors resection and for imatinib treatment outcomes in gastrointestinal stromal tumors.
Rutkowski P; Debiec-Rychter M; Nowecki ZI; Wozniak A; Michej W; Limon J; Siedlecki JA; Jerzak Vel Dobosz A; Grzesiakowska U; Nasierowska-Guttmejer A; Sygut J; Nyckowski P; Krawczyk M; Ruka W
Med Sci Monit; 2007 Nov; 13(11):CR515-522. PubMed ID: 17968300
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant and neoadjuvant therapy for primary GIST.
Eisenberg BL; Smith KD
Cancer Chemother Pharmacol; 2011 Jan; 67 Suppl 1():S3-8. PubMed ID: 21116626
[TBL] [Abstract][Full Text] [Related]
11. A study of the postoperative course in cases of GIST of the stomach. The efficacy of imatinib in cases of recurrence.
Higashi D; Watanabe Y; Hirano K; Shimomura T; Egawa Y; Tomiyasu T; Ishibashi Y; Futami K; Maekawa T; Ota A; Oshige K; Iwashita A
Anticancer Res; 2009 Nov; 29(11):4893-6. PubMed ID: 20032453
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
[TBL] [Abstract][Full Text] [Related]
13. Management of gastrointestinal stromal tumors in the imatinib era: selected case studies.
Benjamin RS; Blanke CD; Blay JY; Bonvalot S; Eisenberg B
Oncologist; 2006 Jan; 11(1):9-20. PubMed ID: 16401709
[TBL] [Abstract][Full Text] [Related]
14. Imatinib adjuvant therapy after surgical excision of gastrointestinal stromal tumour.
Prescrire Int; 2011 Feb; 20(113):38. PubMed ID: 21488587
[No Abstract] [Full Text] [Related]
15. New fronts in the adjuvant treatment of GIST.
Reichardt P; Joensuu H; Blay JY
Cancer Chemother Pharmacol; 2013 Oct; 72(4):715-23. PubMed ID: 23934322
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant imatinib for gastrointestinal stromal tumors: the current situation and problems.
Zhong JH; Ma L; Li LQ; Ru HM; Zhao YN
Scand J Gastroenterol; 2011 Jun; 46(6):645-51. PubMed ID: 21271901
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial].
Zhan WH; Wang PZ; Shao YF; Wu XT; Gu J; Li R; Wan DS; Ding KF; Shi YQ; Yu JR; Lu HS; Zou XM; Bi JW; Sun YH; Lu YF; Chen DD; Zhang XH
Zhonghua Wei Chang Wai Ke Za Zhi; 2006 Sep; 9(5):383-7. PubMed ID: 17043955
[TBL] [Abstract][Full Text] [Related]
18. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
19. Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor.
Hsu KH; Yang TM; Shan YS; Lin PW
Am J Surg; 2007 Aug; 194(2):148-52. PubMed ID: 17618793
[TBL] [Abstract][Full Text] [Related]
20. Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients.
Saied GM; Kensarah AM
Int J Surg; 2010; 8(2):105-8. PubMed ID: 19944196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
